Report cover image

Global Human VEGF Antibody Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 121 Pages
SKU # APRC20354598

Description

Summary

According to APO Research, The global Human VEGF Antibody market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Human VEGF Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Human VEGF Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Human VEGF Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Human VEGF Antibody include Abcam, Abnova, Absolute Antibody, Agrisera, BioLegend, Bio-Rad, Bon Opus Biosciences, Boster and Creative Biomart, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Human VEGF Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human VEGF Antibody.

The Human VEGF Antibody market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Human VEGF Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Human VEGF Antibody Segment by Company

Abcam
Abnova
Absolute Antibody
Agrisera
BioLegend
Bio-Rad
Bon Opus Biosciences
Boster
Creative Biomart
Enzo Life Sciences
ImmunoStar
LifeSpan Biosciences
MilliporeSigma
Novus Biologicals
OriGene
ProMab
R&D Systems
Rockland Immunochemicals
Santa Cruz Biotechnology
Sino Biological
US Biological
Thermo Fisher

Human VEGF Antibody Segment by Type

Rabbit
Mouse
Goat
Others

Human VEGF Antibody Segment by Application

Laboratory
Hospital
Others

Human VEGF Antibody Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human VEGF Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human VEGF Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human VEGF Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human VEGF Antibody manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Human VEGF Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Table of Contents

121 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Human VEGF Antibody Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Human VEGF Antibody Sales Estimates and Forecasts (2020-2031)
1.3 Human VEGF Antibody Market by Type
1.3.1 Rabbit
1.3.2 Mouse
1.3.3 Goat
1.3.4 Others
1.4 Global Human VEGF Antibody Market Size by Type
1.4.1 Global Human VEGF Antibody Market Size Overview by Type (2020-2031)
1.4.2 Global Human VEGF Antibody Historic Market Size Review by Type (2020-2025)
1.4.3 Global Human VEGF Antibody Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Human VEGF Antibody Sales Breakdown by Type (2020-2025)
1.5.2 Europe Human VEGF Antibody Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Human VEGF Antibody Sales Breakdown by Type (2020-2025)
1.5.4 South America Human VEGF Antibody Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Human VEGF Antibody Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Human VEGF Antibody Industry Trends
2.2 Human VEGF Antibody Industry Drivers
2.3 Human VEGF Antibody Industry Opportunities and Challenges
2.4 Human VEGF Antibody Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Human VEGF Antibody Revenue (2020-2025)
3.2 Global Top Players by Human VEGF Antibody Sales (2020-2025)
3.3 Global Top Players by Human VEGF Antibody Price (2020-2025)
3.4 Global Human VEGF Antibody Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Human VEGF Antibody Major Company Production Sites & Headquarters
3.6 Global Human VEGF Antibody Company, Product Type & Application
3.7 Global Human VEGF Antibody Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Human VEGF Antibody Market CR5 and HHI
3.8.2 Global Top 5 and 10 Human VEGF Antibody Players Market Share by Revenue in 2024
3.8.3 2023 Human VEGF Antibody Tier 1, Tier 2, and Tier 3
4 Human VEGF Antibody Regional Status and Outlook
4.1 Global Human VEGF Antibody Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Human VEGF Antibody Historic Market Size by Region
4.2.1 Global Human VEGF Antibody Sales in Volume by Region (2020-2025)
4.2.2 Global Human VEGF Antibody Sales in Value by Region (2020-2025)
4.2.3 Global Human VEGF Antibody Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Human VEGF Antibody Forecasted Market Size by Region
4.3.1 Global Human VEGF Antibody Sales in Volume by Region (2026-2031)
4.3.2 Global Human VEGF Antibody Sales in Value by Region (2026-2031)
4.3.3 Global Human VEGF Antibody Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Human VEGF Antibody by Application
5.1 Human VEGF Antibody Market by Application
5.1.1 Laboratory
5.1.2 Hospital
5.1.3 Others
5.2 Global Human VEGF Antibody Market Size by Application
5.2.1 Global Human VEGF Antibody Market Size Overview by Application (2020-2031)
5.2.2 Global Human VEGF Antibody Historic Market Size Review by Application (2020-2025)
5.2.3 Global Human VEGF Antibody Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Human VEGF Antibody Sales Breakdown by Application (2020-2025)
5.3.2 Europe Human VEGF Antibody Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Human VEGF Antibody Sales Breakdown by Application (2020-2025)
5.3.4 South America Human VEGF Antibody Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Human VEGF Antibody Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Abcam
6.1.1 Abcam Comapny Information
6.1.2 Abcam Business Overview
6.1.3 Abcam Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Abcam Human VEGF Antibody Product Portfolio
6.1.5 Abcam Recent Developments
6.2 Abnova
6.2.1 Abnova Comapny Information
6.2.2 Abnova Business Overview
6.2.3 Abnova Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Abnova Human VEGF Antibody Product Portfolio
6.2.5 Abnova Recent Developments
6.3 Absolute Antibody
6.3.1 Absolute Antibody Comapny Information
6.3.2 Absolute Antibody Business Overview
6.3.3 Absolute Antibody Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Absolute Antibody Human VEGF Antibody Product Portfolio
6.3.5 Absolute Antibody Recent Developments
6.4 Agrisera
6.4.1 Agrisera Comapny Information
6.4.2 Agrisera Business Overview
6.4.3 Agrisera Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Agrisera Human VEGF Antibody Product Portfolio
6.4.5 Agrisera Recent Developments
6.5 BioLegend
6.5.1 BioLegend Comapny Information
6.5.2 BioLegend Business Overview
6.5.3 BioLegend Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.5.4 BioLegend Human VEGF Antibody Product Portfolio
6.5.5 BioLegend Recent Developments
6.6 Bio-Rad
6.6.1 Bio-Rad Comapny Information
6.6.2 Bio-Rad Business Overview
6.6.3 Bio-Rad Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Bio-Rad Human VEGF Antibody Product Portfolio
6.6.5 Bio-Rad Recent Developments
6.7 Bon Opus Biosciences
6.7.1 Bon Opus Biosciences Comapny Information
6.7.2 Bon Opus Biosciences Business Overview
6.7.3 Bon Opus Biosciences Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Bon Opus Biosciences Human VEGF Antibody Product Portfolio
6.7.5 Bon Opus Biosciences Recent Developments
6.8 Boster
6.8.1 Boster Comapny Information
6.8.2 Boster Business Overview
6.8.3 Boster Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Boster Human VEGF Antibody Product Portfolio
6.8.5 Boster Recent Developments
6.9 Creative Biomart
6.9.1 Creative Biomart Comapny Information
6.9.2 Creative Biomart Business Overview
6.9.3 Creative Biomart Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Creative Biomart Human VEGF Antibody Product Portfolio
6.9.5 Creative Biomart Recent Developments
6.10 Enzo Life Sciences
6.10.1 Enzo Life Sciences Comapny Information
6.10.2 Enzo Life Sciences Business Overview
6.10.3 Enzo Life Sciences Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Enzo Life Sciences Human VEGF Antibody Product Portfolio
6.10.5 Enzo Life Sciences Recent Developments
6.11 ImmunoStar
6.11.1 ImmunoStar Comapny Information
6.11.2 ImmunoStar Business Overview
6.11.3 ImmunoStar Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.11.4 ImmunoStar Human VEGF Antibody Product Portfolio
6.11.5 ImmunoStar Recent Developments
6.12 LifeSpan Biosciences
6.12.1 LifeSpan Biosciences Comapny Information
6.12.2 LifeSpan Biosciences Business Overview
6.12.3 LifeSpan Biosciences Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.12.4 LifeSpan Biosciences Human VEGF Antibody Product Portfolio
6.12.5 LifeSpan Biosciences Recent Developments
6.13 MilliporeSigma
6.13.1 MilliporeSigma Comapny Information
6.13.2 MilliporeSigma Business Overview
6.13.3 MilliporeSigma Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.13.4 MilliporeSigma Human VEGF Antibody Product Portfolio
6.13.5 MilliporeSigma Recent Developments
6.14 Novus Biologicals
6.14.1 Novus Biologicals Comapny Information
6.14.2 Novus Biologicals Business Overview
6.14.3 Novus Biologicals Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Novus Biologicals Human VEGF Antibody Product Portfolio
6.14.5 Novus Biologicals Recent Developments
6.15 OriGene
6.15.1 OriGene Comapny Information
6.15.2 OriGene Business Overview
6.15.3 OriGene Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.15.4 OriGene Human VEGF Antibody Product Portfolio
6.15.5 OriGene Recent Developments
6.16 ProMab
6.16.1 ProMab Comapny Information
6.16.2 ProMab Business Overview
6.16.3 ProMab Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.16.4 ProMab Human VEGF Antibody Product Portfolio
6.16.5 ProMab Recent Developments
6.17 R&D Systems
6.17.1 R&D Systems Comapny Information
6.17.2 R&D Systems Business Overview
6.17.3 R&D Systems Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.17.4 R&D Systems Human VEGF Antibody Product Portfolio
6.17.5 R&D Systems Recent Developments
6.18 Rockland Immunochemicals
6.18.1 Rockland Immunochemicals Comapny Information
6.18.2 Rockland Immunochemicals Business Overview
6.18.3 Rockland Immunochemicals Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Rockland Immunochemicals Human VEGF Antibody Product Portfolio
6.18.5 Rockland Immunochemicals Recent Developments
6.19 Santa Cruz Biotechnology
6.19.1 Santa Cruz Biotechnology Comapny Information
6.19.2 Santa Cruz Biotechnology Business Overview
6.19.3 Santa Cruz Biotechnology Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Santa Cruz Biotechnology Human VEGF Antibody Product Portfolio
6.19.5 Santa Cruz Biotechnology Recent Developments
6.20 Sino Biological
6.20.1 Sino Biological Comapny Information
6.20.2 Sino Biological Business Overview
6.20.3 Sino Biological Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Sino Biological Human VEGF Antibody Product Portfolio
6.20.5 Sino Biological Recent Developments
6.21 US Biological
6.21.1 US Biological Comapny Information
6.21.2 US Biological Business Overview
6.21.3 US Biological Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.21.4 US Biological Human VEGF Antibody Product Portfolio
6.21.5 US Biological Recent Developments
6.22 Thermo Fisher
6.22.1 Thermo Fisher Comapny Information
6.22.2 Thermo Fisher Business Overview
6.22.3 Thermo Fisher Human VEGF Antibody Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Thermo Fisher Human VEGF Antibody Product Portfolio
6.22.5 Thermo Fisher Recent Developments
7 North America by Country
7.1 North America Human VEGF Antibody Sales by Country
7.1.1 North America Human VEGF Antibody Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Human VEGF Antibody Sales by Country (2020-2025)
7.1.3 North America Human VEGF Antibody Sales Forecast by Country (2026-2031)
7.2 North America Human VEGF Antibody Market Size by Country
7.2.1 North America Human VEGF Antibody Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Human VEGF Antibody Market Size by Country (2020-2025)
7.2.3 North America Human VEGF Antibody Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Human VEGF Antibody Sales by Country
8.1.1 Europe Human VEGF Antibody Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Human VEGF Antibody Sales by Country (2020-2025)
8.1.3 Europe Human VEGF Antibody Sales Forecast by Country (2026-2031)
8.2 Europe Human VEGF Antibody Market Size by Country
8.2.1 Europe Human VEGF Antibody Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Human VEGF Antibody Market Size by Country (2020-2025)
8.2.3 Europe Human VEGF Antibody Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Human VEGF Antibody Sales by Country
9.1.1 Asia-Pacific Human VEGF Antibody Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Human VEGF Antibody Sales by Country (2020-2025)
9.1.3 Asia-Pacific Human VEGF Antibody Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Human VEGF Antibody Market Size by Country
9.2.1 Asia-Pacific Human VEGF Antibody Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Human VEGF Antibody Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Human VEGF Antibody Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Human VEGF Antibody Sales by Country
10.1.1 South America Human VEGF Antibody Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Human VEGF Antibody Sales by Country (2020-2025)
10.1.3 South America Human VEGF Antibody Sales Forecast by Country (2026-2031)
10.2 South America Human VEGF Antibody Market Size by Country
10.2.1 South America Human VEGF Antibody Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Human VEGF Antibody Market Size by Country (2020-2025)
10.2.3 South America Human VEGF Antibody Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Human VEGF Antibody Sales by Country
11.1.1 Middle East and Africa Human VEGF Antibody Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Human VEGF Antibody Sales by Country (2020-2025)
11.1.3 Middle East and Africa Human VEGF Antibody Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Human VEGF Antibody Market Size by Country
11.2.1 Middle East and Africa Human VEGF Antibody Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Human VEGF Antibody Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Human VEGF Antibody Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Human VEGF Antibody Value Chain Analysis
12.1.1 Human VEGF Antibody Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Human VEGF Antibody Production Mode & Process
12.2 Human VEGF Antibody Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Human VEGF Antibody Distributors
12.2.3 Human VEGF Antibody Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.